28,884 Shares in Harrow, Inc. $HROW Acquired by Brookstone Capital Management

Brookstone Capital Management bought a new stake in Harrow, Inc. (NASDAQ:HROW) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,884 shares of the company’s stock, valued at approximately $1,018,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. University of Texas Texas AM Investment Management Co. purchased a new position in shares of Harrow during the 4th quarter worth $26,000. Raymond James Financial Inc. purchased a new stake in shares of Harrow in the second quarter valued at about $48,000. SBI Securities Co. Ltd. raised its stake in Harrow by 393.5% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock worth $52,000 after purchasing an additional 846 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock valued at $88,000 after purchasing an additional 369 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Harrow by 345.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after buying an additional 2,615 shares during the period. 72.76% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on HROW shares. Zacks Research upgraded Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. Wall Street Zen cut shares of Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Harrow in a research note on Thursday, March 19th. Cantor Fitzgerald lowered their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Weiss Ratings cut shares of Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $69.43.

Insiders Place Their Bets

In other Harrow news, Director Adrienne L. Graves purchased 1,000 shares of the business’s stock in a transaction on Monday, May 18th. The shares were bought at an average cost of $31.07 per share, for a total transaction of $31,070.00. Following the completion of the purchase, the director directly owned 1,000 shares in the company, valued at approximately $31,070. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew R. Boll purchased 3,500 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were acquired at an average cost of $29.90 per share, with a total value of $104,650.00. Following the completion of the acquisition, the chief financial officer directly owned 814,679 shares in the company, valued at $24,358,902.10. The trade was a 0.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 12.80% of the company’s stock.

Harrow Stock Up 1.4%

Shares of NASDAQ:HROW opened at $42.07 on Friday. Harrow, Inc. has a fifty-two week low of $28.54 and a fifty-two week high of $54.85. The firm’s 50 day moving average price is $37.05 and its 200 day moving average price is $41.59. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -102.61 and a beta of 0.28.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. During the same period in the prior year, the company posted ($0.38) earnings per share. As a group, equities research analysts predict that Harrow, Inc. will post 0.29 earnings per share for the current fiscal year.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.